Risultati per: Diagnosi, trattamento e monitoraggio dell’ADHD

Con dose giornaliera in casa di polvere di arachidi

Parte un progetto dell’Aou di Cagliari

Parte un progetto dell’Aou di Cagliari

In Reply We appreciate the comments from Mr Richards-Belle and colleagues and Dr Zarkowski regarding our recently published study. Their comments highlight important considerations in pharmacoepidemiological studies using real-world data.

To the Editor Drs Li and colleagues adopted a method for assessing causality from observational data, a target trial emulation, to compare mortality among individuals with ADHD who received ADHD medication with those who did not. Similar to randomized clinical trials that the method is designed to emulate, the diagnosis of ADHD is made after an independent neuropsychiatric assessment. Yet whether each individual with a diagnosis of ADHD received ADHD medication was not random but was determined by a clinician, based on balancing risk and benefit for each individual patient. Even with an accurate diagnosis of ADHD, there are many relative contraindications for ADHD medication. The accompanying editorial by Drs Levin and colleagues discussed the reluctance of clinicians to prescribe ADHD medication for patients with active substance use disorder or cardiovascular disease. To this list, I would add that many clinicians are reluctant to prescribe ADHD medications to patients with schizophrenia or bipolar disorder. This reluctance is evident in the overrepresentation of substance use disorders (by 39%), cardiovascular disease (by 59%), bipolar disorder (by 33%), and schizophrenia (by 100%) in the group that did not receive ADHD medications compared with the group that did. Each of these comorbid conditions is a well-known risk factor for early mortality and would be expected to increase the relative mortality in the unmedicated group.

To the Editor Dr Li and colleagues report that among individuals diagnosed with attention-deficit/hyperactivity disorder (ADHD), medications to treat ADHD might reduce the 2-year mortality rate. This study has several features warranting further explanation.

Introduction
Children with atopic dermatitis (AD) are more at risk for the neurodevelopmental disorders attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) with parallel increases in global prevalences. Children afflicted with these conditions appear to share similar problems in sensory modulation but investigational studies on the underlying aetiology are scarce. This scoping review aims to find knowledge gaps, collate hypotheses and to summarise available evidence on the shared pathophysiology of AD, ADHD and ASD in children.

Methods and analysis
Our study will follow the methodological manual published by the Joanna Briggs Methodology for Scoping Reviews and will be reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews. The following electronic databases will be searched for studies focused on children with AD and symptoms of ADHD and/or ASD: Medline ALL via Ovid, Embase, Web of Science Core Collection and the Cochrane Central Register of Controlled Trials via Wiley.

Ethics and dissemination
This review does not require ethics approval as it will not be conducted with human participants. We will only use published data. Our dissemination strategy includes peer review publication and conference reports.

Con la Radiomica si può sapere se il paziente risponde a terapie

About 11% of US children aged 5 to 17 years have been diagnosed with attention-deficit/hyperactivity disorder (ADHD), based on data from the National Health Interview Survey conducted between 2020 and 2022. This survey confirms estimates from earlier reports.

Denunciato: medico e infermiera presi a calci dopo il soccorso